Nigeria must not trade its health sovereignty for foreign assistance. Before billions change hands and biological specimens leave its shores, the Tinubu administration must explain what the country stands to gain, what it risks losing, and who ultimately controls the bargain.
There is a bitter irony in a nation seeking a cure for its broken health system signing an agreement that could leave it with more questions than answers. Nigeria needs hospitals, medicines, modern laboratories and well-equipped healthcare workers. It needs every legitimate investment it can secure. But it must not allow the desperation for healthcare funding to cloud its judgment on an agreement whose implications could outlive the money.
The $5bn health deal between Nigeria and the United States promises much. Yet beneath the impressive figures lies a troubling question: Is Nigeria securing a lifeline for its health sector, or opening a door it may struggle to close?
Under the five-year Memorandum of Understanding signed on December 19, 2025, the United States intends to provide nearly $2.1bn in health assistance, while Nigeria is expected to commit nearly $3bn in domestic health expenditure. The programme covers HIV/AIDS, tuberculosis, malaria, polio, maternal and child health, disease surveillance and laboratory systems.
These are urgent priorities. Millions of Nigerians need better access to healthcare, and international cooperation can save lives. But a billion-dollar promise must never become a blank cheque.
The real controversy is not the money. It is the data, the specimens and the terms attached to them.
Under the specimen-sharing agreement, Nigeria is required to initiate the sharing of requested specimens and related data concerning novel and emerging infectious diseases within five days of a US request, unless both parties agree on another timeline. The US government may also share these materials with eligible American entities involved in developing diagnostics and medical countermeasures.
Such cooperation can accelerate scientific discoveries and strengthen responses to dangerous outbreaks. But who sets the limits? Who ensures accountability? And what happens when Nigeria’s biological resources produce a valuable medical breakthrough?
The most disturbing question emerges from Article 5 of the agreement. It provides that if Nigeria terminates the arrangement, termination will not affect the US government’s use of specimens and related data already shared.
In plain language, Nigeria may end the agreement, but it cannot automatically end the use of what it has already handed over.
That provision demands urgent scrutiny. It raises serious questions about the limits of consent, the future use of biological materials, intellectual property, commercial benefits and Nigeria’s ability to protect its interests after the partnership ends.
This does not prove that the United States intends to misuse Nigerian specimens or data. But a responsible government does not wait for abuse to occur before demanding safeguards. The purpose of a contract is to prevent disputes and protect the parties before trouble begins.
Why should Nigeria accept uncertainty where clarity is possible?
Ghana’s experience should serve as a warning. President John Dramani Mahama disclosed that his government rejected a proposed US health compact after its review raised concerns about pathogen information, medical records, financial obligations and regulatory powers. Ghana’s decision does not establish that every provision of its proposed compact was identical to Nigeria’s agreement. It does, however, demonstrate that a government can scrutinise foreign assistance and refuse terms it finds unacceptable.
Nigeria must not confuse speed with wisdom or foreign funding with an obligation to surrender its bargaining power.
There is also the question of whether Abuja can fulfil its side of the bargain. The US contribution is an intended commitment, while Nigeria’s nearly $3bn counterpart contribution represents planned domestic expenditure over five years. Neither figure, by itself, proves that the funds have been fully disbursed or that the promised outcomes will materialise.
The government must explain where the money will come from, how it will be appropriated and released, and what protections will prevent the programme from becoming another ambitious policy undermined by poor implementation.
Nigerians have heard enough grand announcements. They need functioning primary healthcare centres, affordable medicines, reliable diagnostic services and medical professionals who are properly equipped to do their jobs.
The digital health component presents another challenge. The agreement envisages the rollout of electronic health records across all facilities by 2030. Properly managed, these systems could transform patient care and disease surveillance. Without strong safeguards, however, they could expose vast amounts of sensitive medical information to unauthorised access, excessive retention and uses unrelated to public health.
An HIV diagnosis, a reproductive health record or a patient’s medical history is not ordinary data. Its exposure can invite stigma, discrimination and exploitation.
The Nigeria Data Protection Act 2023 provides a framework for protecting personal information, including sensitive health data. The government must explain how the proposed systems will comply with the law, who will have access to the records, where the information will be stored, how long it will be retained and under what conditions it may be shared across borders.
Nigerians must not become data points in a system they neither understand nor control.
The agreement’s emphasis on Christian faith-based healthcare providers also deserves transparent scrutiny. The proposed allocation of approximately $200m to support these institutions could strengthen services in underserved communities. But public-health funding must be guided by demonstrated need, measurable outcomes and fairness. No Nigerian should be disadvantaged because of religious affiliation, and no community should be neglected because it lacks political influence.
Then there is the question of who profits from scientific discoveries.
If Nigerian specimens help produce a diagnostic test, vaccine or treatment, what concrete benefits will return to Nigeria? The agreement provides for acknowledgement of Nigerian contributions and expresses an intention to share relevant findings. It also provides for prioritising Nigeria’s access to certain medical countermeasures, subject to available funds and applicable law.
These provisions are welcome, but they leave room for further questions. Will Nigeria have affordable access to resulting products? Will Nigerian researchers and institutions share in the benefits? Can local manufacturers participate through technology transfer and licensing? What protections apply if a discovery becomes commercially valuable?
Recognition in a scientific publication cannot substitute for equitable access to the fruits of scientific research. Nigeria must not supply the biological building blocks of medical breakthroughs only to find that the resulting products remain beyond the reach of its citizens.
The Tinubu administration must therefore act without delay. It should publish the full agreement and relevant annexes, commission an independent review by legal, scientific and data-protection experts, and invite meaningful scrutiny by the National Assembly, civil society and the wider medical community.
Where the terms are inadequate, Nigeria should negotiate stronger, enforceable protections. These must cover secondary use, onward transfers, data security, commercial benefits, dispute resolution and the consequences of termination. The government must also clarify which obligations survive the agreement and whether further restrictions on the future use of previously transferred specimens and data can be secured.
This is not hostility towards the United States. Nor is it an argument against international health cooperation. It is a demand that cooperation be built on mutual respect rather than unanswered questions.
The United States deserves a reliable partner. Nigeria deserves a fair deal. Both interests can be protected if the agreement is transparent, reciprocal and accountable.
Ultimately, the measure of this partnership will not be the billions announced in diplomatic statements. It will be the lives saved, the diseases controlled, the hospitals strengthened and the medicines Nigerians can actually afford. It will also be measured by whether the country retains meaningful safeguards over its citizens’ medical information and biological resources.
Nigeria must not be so hungry for aid that it forgets the value of what it brings to the table.
Money can be replenished. Trust, once destroyed, is harder to restore. And biological resources surrendered without adequate safeguards may carry consequences long after the funding ends.
The government must prove that this agreement is a partnership worthy of Nigeria’s sovereignty, not a bargain whose hidden costs will emerge when it is too late to renegotiate.
The nation needs the aid. It needs the science. It needs the medicines.
But above all, it needs a government that understands that protecting the health of Nigerians also means protecting their rights.
Aid today must not become a loss of control tomorrow.